Recent Quotes (30 days)

You have no recent quotes
chg | %

Aptose Biosciences Inc  

(Public, TSE:APS)   Watch this stock  
Find more results for TSE:LOR
1.38
-0.02 (-1.43%)
May 29 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.38 - 1.40
52 week 1.05 - 5.13
Open 1.38
Vol / Avg. 6,500.00/92,069.00
Mkt cap 26.52M
P/E     -
Div/yield     -
EPS -1.31
Shares 18.94M
Beta 2.07
Inst. own     -
Aug 8, 2017
Q2 2017 Aptose Biosciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 21, 2017
Aptose Biosciences Inc Annual Shareholders Meeting (Estimated) - 10:00AM EDT - Add to calendar
Jun 6, 2017
Aptose Biosciences Inc Annual Shareholders Meeting - 10:00AM EDT - Add to calendar
May 11, 2017
Q1 2017 Aptose Biosciences Inc Earnings Call
May 11, 2017
Q1 2017 Aptose Biosciences Inc Earnings Release
May 1, 2017
Aptose Biosciences Inc at Bloom Burton & Co. Healthcare Investor Conference
Mar 14, 2017
Aptose Biosciences Inc at ROTH Conference - Webcast
Mar 8, 2017
Aptose Biosciences Inc at Cowen Health Care Conference - Webcast
  

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -143.85% -113.38%
Return on average equity -173.15% -129.66%
Employees 21 -
CDP Score - -

Address

5955 Airport Rd Suite 228
MISSISSAUGA, ON L4V 1R9
Canada
+1-647-4799828 (Phone)
+1-416-7982200 (Fax)

Website links

Description

Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.

Officers and directors

William Glenn Rice Chairman of the Board, President, Chief Executive Officer
Gregory Kwok Lee Chow Chief Financial Officer, Senior Vice President
Denis R. Burger Ph.D. Independent Director
Age: 70
Erich M. Platzer M.D., Ph.D. Independent Director
Bradley Thompson Independent Director
Mark D. Vincent M.D. Independent Director
Warren Whitehead Independent Director